(NaturalNews) There’s a good chance that the vast majority of people who receive it won’t derive any benefits whatsoever. But that isn’t stopping British drug giant GlaxoSmithKline (GSK) from seeking regulatory approval for a new vaccine for malaria, known as RTS,S, that a recent study determined is only about 30 percent effective at preventing severe cases of the disease, which has no recognized cure.
Published in the journal PLOS Medicine, the study found that RTS,S provides limited protection in select individuals for up to a year-and-a-half, at most. In children five to 17 years of age, the vaccine can supposedly prevent infection up to 46 percent of the time, and severe infection up to 34 percent of the time. These figures, claim GSK, are good enough to warrant the drug’s approval, even though no other vaccine with such a poor success record has ever been approved.
“It’s a pretty good vaccine,” stated Mary Hamel, a medical epidemiologist at the U.S. Centers for Disease Control and Prevention (CDC), one of the authors of the new study. “We were looking for 30 percent or higher.”